In a milestone event for the cannabis industry in Europe and the UK, on Wednesday, cannabis shares were traded on the London Stock Exchange (LSE) for the first time.
It came as MGC Pharmaceuticals was listed on the LSE after the company successfully raised £6.5 million (€7.41 million) through an oversubscribed funding drive which saw the company decline millions in investment funding.
The company’s managing director, Roby Zomer, said it is “proud to make history as the first medical cannabis company on [the] historic exchange”.
MGC Pharma is an Australian-listed company. Its two flagship phytocannabinoid-derived medicines, CannEpil, and CogniCann are designed to treat refractory epilepsy, and improve dementia and Alzheimer’s patients quality of life.
The company has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution format via its network of commercial partners, meaning it poised to supply the global market.
Europe’s medical cannabis market is believed to have massive potential.
In 2020, Marijuana Business Daily estimated that the European legal medical cannabis market one day eclipse North America’s. In the USA, the legal marijuana industry was estimated to have a value of $13.6 billion (€11.23 billion) in 2019.
Malta is an EU leader for its cannabis law. In 2018, it enacted the Production of Cannabis for Medicinal and Research Purposes Act, which legalised the production of cannabis for medical purposes.
Trump’s 20% tariffs on EU imports: Limited direct impact on Malta, but potential indirect effects
Industries like iGaming may now reconsider moving to the US, reinforcing Europe’s position as a hub
European airlines push to cut compensation for delays under 5 hours
The regulation currently covers up to 3 hours of delay
KM Airlines abandons Catania schedule for winters
Flights will operate during peak summer months